免疫检查点抑制剂对癌症患者甲状腺功能的影响

doi:10.3969/j.issn.2095-1264.2022.02.10

首页 > 过刊浏览>2022年第2期 >204-207. DOI:10.3969/j.issn.2095-1264.2022.02.10

免疫检查点抑制剂对癌症患者甲状腺功能的影响
DOI:
                        10.3969/j.issn.2095-1264.2022.02.10
                    
作者:
                        
                        
                    
作者单位:1.广州医科大学附属第五医院，广东 广州，510000;2.南方医科大学南方医院，广东 广州，510515
作者简介:曾洁，女，硕士，主管药师，研究方向：临床药学。
通讯作者:谢聪，男，博士，主管药师，研究方向：生物药剂学与药代动力学、蛋白质组学。
中图分类号:R730.6
基金项目:

The impact of immune checkpoint inhibitors on thyroid function of cancer patients

Author:

Affiliation:

1.The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510000, China;2.Nangfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

目的探讨免疫检查点抑制剂（ICI）对癌症患者甲状腺功能的影响。方法回顾性分析39例接受ICIs治疗的癌症患者，治疗期间监测患者甲状腺功能指标。结果 39例采用ICIs治疗的患者中，5例（12.8%）发生甲状腺功能减退，需要甲状腺激素替代治疗。甲状腺功能减退发生在治疗早期，平均发生时间为治疗第2周期。经左甲状腺素钠片治疗后，随访期间患者甲状腺功能未恢复。结论 ICIs可引起甲状腺功能减退，可能发生在治疗早期，建议使用ICIs期间密切监测患者的甲状腺功能。

Abstract:

Objective To investigate the effects of immune checkpoint inhibitors (ICIs) on the thyroid function of cancer patients.Methods Thirty-nine cancer patients with ICIs treatment were retrospectively analyzed in this study. All patients had their thyroid function indexes monitored during treatment.Results Of the 39 patients treated with ICIs, 5 cases (12.8%) had hypothyroidism and required thyroid hormone replacement therapy. Hypothyroidism occurred early at the ICIs treatment, with an average time at the second cycle. No evident recovery of thyroid function was observed during the follow up after treatment with levothyroxine sodium tablets.Conclusion Immune checkpoint inhibitors may cause hypothyroidism with early onset. Monitoring thyroid function is recommended during the use of immune checkpoint inhibitors.